Literature DB >> 28536173

Optimal Timing of Diffusion-Weighted Imaging to Avoid False-Negative Findings in Patients With Transient Ischemic Attack.

Kenji Shono1, Junichiro Satomi2, Yoshiteru Tada1, Yasuhisa Kanematsu1, Nobuaki Yamamoto1, Yuishin Izumi1, Ryuji Kaji1, Masafumi Harada1, Shinji Nagahiro1.   

Abstract

BACKGROUND AND
PURPOSE: We aimed to investigate the optimal timing of diffusion-weighted imaging (DWI) in patients with transient ischemic attack (TIA).
METHODS: Seventy-three consecutive patients with TIA underwent DWI on admission (initial DWI) and at 24 hours after admission (second DWI). Patients were divided into 2 groups based on initial DWI findings in relation to the second examination: false negative (group 1) and other (group 2). The probability of initial false-negative findings was determined for each hour from TIA onset to initial DWI. Multivariate analysis was used to evaluate the independent risk factors associated with false-negative findings on initial DWI.
RESULTS: Of the 73 patients examined (56 men; mean age, 68 years), 9 (12%) were categorized into group 1. The latency from TIA onset to initial DWI was 1.7±0.6 hours for group 1 (range, 1-2.8 hours) and 3.3±2.6 hours for group 2 (range, 35 minutes to 12 hours). The probability of false-negative findings on initial DWI decreased in a time-dependent manner (25%, 21%, and 7% for 1, 2, and 3 hours, respectively), and no false-negative findings were observed on initial DWI performed at >3 hours from symptom onset. Short latency (≤2 hours) from TIA onset to initial DWI was an independent risk factor related to false-negative findings (odds ratio, 13.11; 95% confidence interval, 1.07-161.38; P=0.045).
CONCLUSIONS: If the duration between TIA symptom onset and initial DWI is <2 hours, a repeat examination should be performed to minimize the risk of false-positive findings.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  infarction; magnetic resonance imaging; multivariate analysis; odds ratio; risk factors

Mesh:

Year:  2017        PMID: 28536173     DOI: 10.1161/STROKEAHA.117.014576

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  7 in total

1.  Plasma Exosomal miR-450b-5p as a Possible Biomarker and Therapeutic Target for Transient Ischaemic Attacks in Rats.

Authors:  XiuMei Luo; Wei Wang; DongBin Li; Chen Xu; Bao Liao; FengMei Li; Xia Zhou; Wu Qin; Jingli Liu
Journal:  J Mol Neurosci       Date:  2019-07-31       Impact factor: 3.444

Review 2.  False-negative diagnostic imaging of Wallenberg's syndrome by diffuse-weighted imaging: a case report and literature review.

Authors:  Yanbin Wang; Yao Liu; Yu Wang; Yuchen Li; Pei Wu; Huaizhang Shi
Journal:  Neurol Sci       Date:  2018-04-07       Impact factor: 3.307

3.  Clinical skills or high-tech MR in TIA patients: what makes the difference?

Authors:  Riccardo Altavilla; Sabrina Anticoli; Michele Pellizzaro Venti; Monica Acciarresi; Andrea Alberti; Valeria Caso; Cataldo D'Amore; Francesca Romana Pezzella; Michele Venti; Giancarlo Agnelli; Maurizio Paciaroni
Journal:  Neurol Sci       Date:  2018-08-28       Impact factor: 3.307

Review 4.  Emergency Department (ED) Triage for Transient Ischemic Attack (TIA).

Authors:  Carlo W Cereda; Jean-Marc Olivot
Journal:  Curr Atheroscler Rep       Date:  2018-09-25       Impact factor: 5.113

Review 5.  Recent advances in the management of transient ischemic attacks.

Authors:  Camilo R Gomez; Michael J Schneck; Jose Biller
Journal:  F1000Res       Date:  2017-10-26

6.  Dysphasia is associated with diffusion-weighted MRI abnormalities in patients with transient neurological symptoms.

Authors:  Zejin Jia; Yangguang Song; Wenli Hu
Journal:  Neurol Sci       Date:  2020-02-07       Impact factor: 3.307

7.  Usefulness of multiphase computed tomography angiography in a patient with transient ischemic attack in the hyperacute phase: A case report.

Authors:  Seungho Lee; Jun Soo Byun; Mi Sun Jung; Jeong-Min Kim; Taek-Kyun Nam
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.